搜索结果：leukemia

The complexities inherent to leukemia, multifaceted cancer affecting white blood cells, pose considerable diagnostic and treatment challenges, primarily due to reliance on laborious morphological analyses and expert judgment that are susceptible to errors. Addressing these challenges, this study presents a refined, comprehensive strategy leveraging advanced deep-learning techniques for the classification of leukemia subtypes. We commence by developing a hierarchical label taxonomy, paving the way for differentiating between various subtypes of leukemia. The research further introduces a novel hierarchical approach inspired by clinical procedures capable of accurately classifying diverse types of leukemia alongside reactive and healthy cells. An integral part of this study involves a meticulous examination of the performance of Convolutional Neural Networks (CNNs) and Vision Transformers (ViTs) as classifiers. The proposed method exhibits an impressive success rate, achieving approximately 90\% accuracy across all leukemia subtypes, as substantiated by our experimental results. A visual representation of the experimental findings is provided to enhance the model's explainability and

A mutation in the DNA of a single cell that compromises its function initiates leukemia,leading to the overproduction of immature white blood cells that encroach upon the space required for the generation of healthy blood cells.Leukemia is treatable if identified in its initial stages. However,its diagnosis is both arduous and time consuming. This study proposes a novel approach for diagnosing leukemia across four stages Benign,Early,Pre,and Pro using deep learning techniques.We employed two Convolutional Neural Network (CNN) models as MobileNetV2 with an altered head and a custom model. The custom model consists of multiple convolutional layers,each paired with corresponding max pooling layers.We utilized MobileNetV2 with ImageNet weights,adjusting the head to integrate the final results.The dataset used is the publicly available "Acute Lymphoblastic Leukemia (ALL) Image Dataset", and we applied the Synthetic Minority Oversampling Technique (SMOTE) to augment and balance the training dataset.The custom model achieved an accuracy of 98.6%, while MobileNetV2 attained a superior accuracy of 99.69%. The pretrained model showed promising results,indicating an increased likelihood of re

Microscopic evaluation of white blood cell morphology is central to leukemia diagnosis, yet current deep learning models often act as black boxes, limiting clinical trust and adoption. We introduce HemBLIP, a vision language model designed to generate interpretable, morphology aware descriptions of peripheral blood cells. Using a newly constructed dataset of 14k healthy and leukemic cells paired with expert-derived attribute captions, we adapt a general-purpose VLM via both full fine-tuning and LoRA based parameter efficient training, and benchmark against the biomedical foundation model MedGEMMA. HemBLIP achieves higher caption quality and morphological accuracy, while LoRA adaptation provides further gains with significantly reduced computational cost. These results highlight the promise of vision language models for transparent and scalable hematological diagnostics.

Acute Myeloid Leukemia (AML) is one of the most life-threatening type of blood cancers, and its accurate classification is considered and remains a challenging task due to the visual similarity between various cell types. This study addresses the classification of the multiclasses of AML cells Utilizing YOLOv12 deep learning model. We applied two segmentation approaches based on cell and nucleus features, using Hue channel and Otsu thresholding techniques to preprocess the images prior to classification. Our experiments demonstrate that YOLOv12 with Otsu thresholding on cell-based segmentation achieved the highest level of validation and test accuracy, both reaching 99.3%.

Leukemia diagnosis and monitoring rely increasingly on high-throughput image data, yet conventional clustering methods lack the flexibility to accommodate evolving cellular patterns and quantify uncertainty in real time. We introduce Adaptive and Dynamic Neuro-Fuzzy Clustering, a novel streaming-capable framework that combines Convolutional Neural Network-based feature extraction with an online fuzzy clustering engine. ADNF initializes soft partitions via Fuzzy C-Means, then continuously updates micro-cluster centers, densities, and fuzziness parameters using a Fuzzy Temporal Index (FTI) that measures entropy evolution. A topology refinement stage performs density-weighted merging and entropy-guided splitting to guard against over- and under-segmentation. On the C-NMC leukemia microscopy dataset, our tool achieves a silhouette score of 0.51, demonstrating superior cohesion and separation over static baselines. The method's adaptive uncertainty modeling and label-free operation hold immediate potential for integration within the INFANT pediatric oncology network, enabling scalable, up-to-date support for personalized leukemia management.

Thousands of individuals succumb annually to leukemia alone. As artificial intelligence-driven technologies continue to evolve and advance, the question of their applicability and reliability remains unresolved. This study aims to utilize image processing and deep learning methodologies to achieve state-of-the-art results for the detection of Acute Lymphoblastic Leukemia (ALL) using data that best represents real-world scenarios. ALL is one of several types of blood cancer, and it is an aggressive form of leukemia. In this investigation, we examine the most recent advancements in ALL detection, as well as the latest iteration of the YOLO series and its performance. We address the question of whether white blood cells are malignant or benign. Additionally, the proposed models can identify different ALL stages, including early stages. Furthermore, these models can detect hematogones despite their frequent misclassification as ALL. By utilizing advanced deep learning models, namely, YOLOv8, YOLOv11, ResNet50 and Inception-ResNet-v2, the study achieves accuracy rates as high as 99.7%, demonstrating the effectiveness of these algorithms across multiple datasets and various real-world si

Leukemia diagnosis primarily relies on manual microscopic analysis of bone marrow morphology supported by additional laboratory parameters, making it complex and time consuming. While artificial intelligence (AI) solutions have been proposed, most utilize private datasets and only cover parts of the diagnostic pipeline. Therefore, we present a large, high-quality, publicly available leukemia bone marrow dataset spanning the entire diagnostic process, from cell detection to diagnosis. Using this dataset, we further propose methods for cell detection, cell classification, and diagnosis prediction. The dataset comprises 246 pediatric patients with diagnostic, clinical and laboratory information, over 40 000 cells with bounding box annotations and more than 28 000 of these with high-quality class labels, making it the most comprehensive dataset publicly available. Evaluation of the AI models yielded an average precision of 0.96 for the cell detection, an area under the curve of 0.98, and an F1-score of 0.61 for the 33-class cell classification, and a mean F1-score of 0.90 for the diagnosis prediction using predicted cell counts. While the proposed approaches demonstrate their usefulnes

Acute Leukemia is the most common hematologic malignancy in children and adolescents. A key methodology in the diagnostic evaluation of this malignancy is immunophenotyping based on Multiparameter Flow Cytometry (FCM). However, this approach is manual, and thus time-consuming and subjective. To alleviate this situation, we propose in this paper the FCM-Former, a machine learning, self-attention based FCM-diagnostic tool, automating the immunophenotyping assessment in Childhood Acute Leukemia. The FCM-Former is trained in a supervised manner, by directly using flow cytometric data. Our FCM-Former achieves an accuracy of 96.5% assigning lineage to each sample among 960 cases of either acute B-cell, T-cell lymphoblastic, and acute myeloid leukemia (B-ALL, T-ALL, AML). To the best of our knowledge, the FCM-Former is the first work that automates the immunophenotyping assessment with FCM data in diagnosing pediatric Acute Leukemia.

Leukemia (blood cancer) is an unusual spread of White Blood Cells or Leukocytes (WBCs) in the bone marrow and blood. Pathologists can diagnose leukemia by looking at a person's blood sample under a microscope. They identify and categorize leukemia by counting various blood cells and morphological features. This technique is time-consuming for the prediction of leukemia. The pathologist's professional skills and experiences may be affecting this procedure, too. In computer vision, traditional machine learning and deep learning techniques are practical roadmaps that increase the accuracy and speed in diagnosing and classifying medical images such as microscopic blood cells. This paper provides a comprehensive analysis of the detection and classification of acute leukemia and WBCs in the microscopic blood cells. First, we have divided the previous works into six categories based on the output of the models. Then, we describe various steps of detection and classification of acute leukemia and WBCs, including Data Augmentation, Preprocessing, Segmentation, Feature Extraction, Feature Selection (Reduction), Classification, and focus on classification step in the methods. Finally, we divi

Acute lymphoblastic leukemia (ALL) is the most malignant form of leukemia and the most common cancer in adults and children. Traditionally, leukemia is diagnosed by analyzing blood and bone marrow smears under a microscope, with additional cytochemical tests for confirmation. However, these methods are expensive, time consuming, and highly dependent on expert knowledge. In recent years, deep learning, particularly Convolutional Neural Networks (CNNs), has provided advanced methods for classifying microscopic smear images, aiding in the detection of leukemic cells. These approaches are quick, cost effective, and not subject to human bias. However, most methods lack the ability to quantify uncertainty, which could lead to critical misdiagnoses. In this research, hybrid deep learning models (InceptionV3-GRU, EfficientNetB3-GRU, MobileNetV2-GRU) were implemented to classify ALL. Bayesian optimization was used to fine tune the model's hyperparameters and improve its performance. Additionally, Deep Ensemble uncertainty quantification was applied to address uncertainty during leukemia image classification. The proposed models were trained on the publicly available datasets ALL-IDB1 and AL

The Internet of Things (IoT) is a concept by which objects find identity and can communicate with each other in a network. One of the applications of the IoT is in the field of medicine, which is called the Internet of Medical Things (IoMT). Acute Lymphocytic Leukemia (ALL) is a type of cancer categorized as a hematic disease. It usually begins in the bone marrow due to the overproduction of immature White Blood Cells (WBCs or leukocytes). Since it has a high rate of spread to other body organs, it is a fatal disease if not diagnosed and treated early. Therefore, for identifying cancerous (ALL) cells in medical diagnostic laboratories, blood, as well as bone marrow smears, are taken by pathologists. However, manual examinations face limitations due to human error risk and time-consuming procedures. So, to tackle the mentioned issues, methods based on Artificial Intelligence (AI), capable of identifying cancer from non-cancer tissue, seem vital. Deep Neural Networks (DNNs) are the most efficient machine learning (ML) methods. These techniques employ multiple layers to extract higher-level features from the raw input. In this paper, a Convolutional Neural Network (CNN) is applied alo

The interactions between tumor cells and the immune system play a crucial role in cancer evolution. In this study, we explore how these interactions influence cancer progression by modeling the relationships among naive T cells, effector T cells, and chronic myeloid leukemia cells. We examine the existence of equilibria, the asymptotic stability of the positive steady state, and the global stability of the tumor-free equilibrium. Additionally, we develop a partial differential equation to describe the conditions under which the concentration of cancer cells reaches a level that allows for effective control of cancer evolution. Finally, we apply our proposed model to investigate optimal treatment strategies that aim to minimize both the concentration of cancer cells at the end of treatment and the accumulation of tumor burden, as well as the cost associated with treatment during the intervention period. Our study reveals an optimal therapeutic protocol using optimal control theory. We perform numerical simulations to illustrate our theoretical results and to explore the dynamic behavior of the system and optimal therapeutic protocols. The simulations indicate that the optimal treatm

This study presents a mathematical model describing cloned hematopoiesis in chronic myeloid leukemia (CML) through a nonlinear system of differential equations. The primary objective is to understand the progression from healthy hematopoiesis to the chronic and accelerated-acute phases in myeloid leukemia. The model incorporates intrinsic cellular division events in hematopoiesis and delineates the evolution of chronic myeloid leukemia into five compartments: cycling stem cells, quiescent stem cells, progenitor cells, differentiated cells and terminally differentiated cells. Our analysis reveals the existence of three distinct non-zero steady states within the dynamical system, representing healthy hematopoiesis, the chronic phase and the accelerated-acute stage of the disease. We investigate the local and global stability of these steady states and provide a characterization of the hematopoietic states based on this analysis. Additionally, numerical simulations are included to illustrate the theoretical results.

Accurate classification of Acute Lymphoblastic Leukemia (ALL) from peripheral blood smear images is essential for early diagnosis and effective treatment planning. This study investigates the use of transfer learning with pretrained convolutional neural networks (CNNs) to improve diagnostic performance. To address the class imbalance in the dataset of 3,631 Hematologic and 7,644 ALL images, we applied extensive data augmentation techniques to create a balanced training set of 10,000 images per class. We evaluated several models, including ResNet50, ResNet101, and EfficientNet variants B0, B1, and B3. EfficientNet-B3 achieved the best results, with an F1-score of 94.30%, accuracy of 92.02%, andAUCof94.79%,outperformingpreviouslyreported methods in the C-NMCChallenge. Thesefindings demonstrate the effectiveness of combining data augmentation with advanced transfer learning models, particularly EfficientNet-B3, in developing accurate and robust diagnostic tools for hematologic malignancy detection.

Leukemia, a severe form of blood cancer, claims thousands of lives each year. This study focuses on the detection of Acute Lymphoblastic Leukemia (ALL) using advanced image processing and deep learning techniques. By leveraging recent advancements in artificial intelligence, the research evaluates the reliability of these methods in practical, real-world scenarios. Specifically, it examines the performance of state-of-the-art YOLO models, including YOLOv8 and YOLOv11, to distinguish between malignant and benign white blood cells and accurately identify different stages of ALL, including early stages. Moreover, the models demonstrate the ability to detect hematogones, which are frequently misclassified as ALL. With accuracy rates reaching 98.8%, this study highlights the potential of these algorithms to provide robust and precise leukemia detection across diverse datasets and conditions.

Acute Myeloid Leukemia (AML) is a highly aggressive blood cancer with low survival rates. Hence, emphasizing the importance of the urgent need for effective treatment modalities. In recent times, the advances in cancer genomics have increased our understanding of AML, as a result, enabling precision oncologists to develop personalized treatment based on individual genetic features and increase the survival rate. However, there is a lack of understanding of how effectively genetic features can be used to predict which drugs are the most suitable for individual-tailored treatment. Therefore, this study explores the potential of Support Vector Regression (SVR) in predicting drug sensitivity of AML patients solely based on their genetic profile. The paper utilized a dataset from Genomics of Drug Sensitivity (GDSC) and developed a precise model that identified the most significant genetic features affecting drug response and achieved promising results with an R-squared score of 0.9523 on the validation set and 0.8928 on the test set.

Earlier diagnosis of Leukemia can save thousands of lives annually. The prognosis of leukemia is challenging without the morphological information of White Blood Cells (WBC) and relies on the accessibility of expensive microscopes and the availability of hematologists to analyze Peripheral Blood Samples (PBS). Deep Learning based methods can be employed to assist hematologists. However, these algorithms require a large amount of labeled data, which is not readily available. To overcome this limitation, we have acquired a realistic, generalized, and large dataset. To collect this comprehensive dataset for real-world applications, two microscopes from two different cost spectrums (high-cost HCM and low-cost LCM) are used for dataset capturing at three magnifications (100x, 40x, 10x) through different sensors (high-end camera for HCM, middle-level camera for LCM and mobile-phone camera for both). The high-sensor camera is 47 times more expensive than the middle-level camera and HCM is 17 times more expensive than LCM. In this collection, using HCM at high resolution (100x), experienced hematologists annotated 10.3k WBC types (14) and artifacts, having 55k morphological labels (Cell Si

Swift and accurate blood smear analysis is an effective diagnostic method for leukemia and other hematological malignancies. However, manual leukocyte count and morphological evaluation using a microscope is time-consuming and prone to errors. Conventional image processing methods also exhibit limitations in differentiating cells due to the visual similarity between malignant and benign cell morphology. This limitation is further compounded by the skewed training data that hinders the extraction of reliable and pertinent features. In response to these challenges, we propose an optimized Coupled Transformer Convolutional Network (CoTCoNet) framework for the classification of leukemia, which employs a well-designed transformer integrated with a deep convolutional network to effectively capture comprehensive global features and scalable spatial patterns, enabling the identification of complex and large-scale hematological features. Further, the framework incorporates a graph-based feature reconstruction module to reveal the hidden or unobserved hard-to-see biological features of leukocyte cells and employs a Population-based Meta-Heuristic Algorithm for feature selection and optimizat

Automated disease diagnosis using medical image analysis relies on deep learning, often requiring large labeled datasets for supervised model training. Diseases like Acute Myeloid Leukemia (AML) pose challenges due to scarce and costly annotations on a single-cell level. Multiple Instance Learning (MIL) addresses weakly labeled scenarios but necessitates powerful encoders typically trained with labeled data. In this study, we explore Self-Supervised Learning (SSL) as a pre-training approach for MIL-based AML subtype classification from blood smears, removing the need for labeled data during encoder training. We investigate the three state-of-the-art SSL methods SimCLR, SwAV, and DINO, and compare their performance against supervised pre-training. Our findings show that SSL-pretrained encoders achieve comparable performance, showcasing the potential of SSL in MIL. This breakthrough offers a cost-effective and data-efficient solution, propelling the field of AI-based disease diagnosis.